Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > Greenhill advised Blackstone in the past on Health acq.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by Forsbureon May 06, 2016 4:42pm
177 Views
Post# 24849513

Greenhill advised Blackstone in the past on Health acq.

Greenhill advised Blackstone in the past on Health acq.
25-Jan-07
$3.3 billion
Target: 

Cardinal Health, Inc., Pharmaceutical Technologies and Services division

Acquiror: 
The Blackstone Group

Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries

Maybe there is a reason why CXR selected Greenhill as the advisor?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities